Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
101.932,40
-0,47%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Serina Therapeutics Inc (SER) Serina Therapeutics Inc (SER) Notizie

SER

Serina Therapeutics (SER)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:SER
DataOraFonteTitoloSimboloCompagnia
15/01/202522:05GlobeNewswire Inc.Serina Therapeutics Announces Sale of UniverXome SubsidiaryAMEX:SERSerina Therapeutics Inc
14/01/202523:25GlobeNewswire Inc.Serina Therapeutics Welcomes Karen J. Wilson to its Board of DirectorsAMEX:SERSerina Therapeutics Inc
06/01/202522:07Edgar (US Regulatory)Form 8-K - Current reportAMEX:SERSerina Therapeutics Inc
16/12/202412:00GlobeNewswire Inc.Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024AMEX:SERSerina Therapeutics Inc
11/12/202412:05GlobeNewswire Inc.Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity SummitAMEX:SERSerina Therapeutics Inc
09/12/202422:45Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]AMEX:SERSerina Therapeutics Inc
02/12/202423:22GlobeNewswire Inc.Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease PatientsAMEX:SERSerina Therapeutics Inc
22/11/202422:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:SERSerina Therapeutics Inc
12/11/202423:00GlobeNewswire Inc.Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business HighlightsAMEX:SERSerina Therapeutics Inc
12/11/202422:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:SERSerina Therapeutics Inc
11/11/202423:40GlobeNewswire Inc.Serina Therapeutics Makes Grants to New Employees Under Inducement PlanAMEX:SERSerina Therapeutics Inc
06/11/202422:45Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:SERSerina Therapeutics Inc
06/11/202422:31Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:SERSerina Therapeutics Inc
06/11/202412:32Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:SERSerina Therapeutics Inc
01/11/202414:15Edgar (US Regulatory)Form DEFC14A - Definitive proxy statement, contested solicitationsAMEX:SERSerina Therapeutics Inc
02/10/202414:30GlobeNewswire Inc.Serina Therapeutics to Present at the 14th Annual Injectables SummitAMEX:SERSerina Therapeutics Inc
17/09/202400:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:SERSerina Therapeutics Inc
05/09/202400:42GlobeNewswire Inc.Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAMEX:SERSerina Therapeutics Inc
23/08/202423:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansAMEX:SERSerina Therapeutics Inc
09/08/202422:15GlobeNewswire Inc.Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business HighlightsAMEX:SERSerina Therapeutics Inc
29/07/202414:30GlobeNewswire Inc.Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics SummitAMEX:SERSerina Therapeutics Inc
18/07/202423:00GlobeNewswire Inc.Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and FormulationAMEX:SERSerina Therapeutics Inc
17/07/202423:07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:SERSerina Therapeutics Inc
10/07/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:SERSerina Therapeutics Inc
14/05/202422:05GlobeNewswire Inc.Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business HighlightsAMEX:SERSerina Therapeutics Inc
17/04/202422:05GlobeNewswire Inc.Serina Therapeutics Appoints Dr. Simba Gill as Executive ChairmanAMEX:SERSerina Therapeutics Inc
26/03/202422:04GlobeNewswire Inc.Serina Therapeutics Announces Completion of Merger with AgeX TherapeuticsAMEX:SERSerina Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:SER

La tua Cronologia

BIT
STMMI
ST Microelectronics
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
G
Generali
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
ENEL
Enel
BIT
PRY
Prysmian
BIT
CPR
Davide Campari
BIT
BAMI
Banco BPM
BIT
IVG
Iveco Group NV
BIT
SPM
Saipem
BIT
MONC
Moncler
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci